AN Venture Partners (ANV), a global biotech venture capital fund, announced the addition of Jun Hashimoto as Partner.
Mr. Hashimoto joins Managing Partner Ken Horne Kawashima, Partner Takashi Futami, and Operating Partner Ali Nowacek to strengthen ANV’s leadership team. He will be based in Tokyo, providing financial and operational support with fundraising as well as to the companies in which ANV invests.
“We are delighted to welcome Jun to ANV’s leadership team,” said Ken Horne, Managing Partner. “Jun has extensive experience in the financial and pharmaceutical industries, as well as in the healthcare sector, and we look forward to his leadership in key areas such as LP fundraising, communications, and portfolio company financing. I am confident that his practical skills and strategic viewpoints will further accelerate the realization of ANV’s vision to identify innovative scientific seeds in Japan and develop them into world-class biotechnology companies.”
“I am strongly determined to achieve our goal of ‘leveraging Japan-originated technology to deliver superior medicines to the world’,” said Mr. Hashimoto, the newly joined partner of ANV. “Based on my experience in the financial and pharmaceutical industries, as well as my work at a healthcare operator supporting hard-to-treat patients, I aim to support the creation of innovative therapeutic medicines that will help patients, through the companies in which we invest, from right here in Japan. I am determined to tackle new challenges at ANV to realize this goal.”
Jun Hashimoto, Partner
Hashimoto brings extensive expertise in M&A and fundraising advisory as well as investments in startups, with a particular focus on the healthcare sector. Prior to joining ANV, he served as the Chief Financial Officer of CUC Inc., a healthcare startup, where he oversaw finance, corporate planning, financial management, investor relations, and other functions. During his tenure, he led the company’s IPO on the Tokyo Stock Exchange, syndicated loan financing, and the execution of both domestic and international M&A transactions.
Prior to that, he spent over 14 years at Goldman Sachs Group, where he advised pharmaceutical, medical device, and consumer goods companies on M&A and financing transactions. In particular, he advised major domestic and international pharmaceutical companies on the acquisition of pharmaceutical and biotech companies, as well as the divestiture and licensing of products and R&D pipelines.
About AN Venture Partners
ANV is a Tokyo and San Francisco-based biotech venture capital firm. ANV is dedicated to building high impact global biotech companies and specializes in sourcing scientific opportunities from Japan.
Media Contacts
Email: info@an.vc